Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day.

The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec

The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec

Mark Vickery headshot

Top Stock Reports for Netflix, Toyota & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM), and AbbVie (ABBV).

Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom

Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom

Tracey Ryniec headshot

5 Innovative Companies That Will Pay You Cold Hard Cash

Who says you have to own "boring" utilities, insurers and telecoms to get big dividends?

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Kaustav Ghosh headshot

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

Kinjel Shah headshot

Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

Benjamin Rains headshot

2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility

Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

Benjamin Rains headshot

3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records

Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...

Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs

AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.

AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod

AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.

Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife

The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife

Sheraz Mian headshot

Q4 Earnings Season Scorecard and Analyst Reports for Exxon, AbbVie & Caterpillar

We have provided a real-time update on the Q4 earnings season in today's Research Daily, in addition to featuring new research reports on Exxon (XOM), AbbVie (ABBV) and Caterpillar (CAT).

Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.

What Makes AbbVie (ABBV) a New Buy Stock

AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ABBV or LLY: Which Is the Better Value Stock Right Now?

ABBV vs. LLY: Which Stock Is the Better Value Option?